Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells

Blood

Volumn 117, Issue 15, 2011, Pages 4154-4161

  Brunner, Patrick M ^a   Heier, Patricia C ^a   Mihaly Bison, Judit ^a   Priglinger, Ute ^a   Binder, Bernd R ^a   Prager, Gerald W ^a,b  

^a Department of Vascular Biology and Thrombosis Research   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DENSITY ENHANCED PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 79954601682     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307694     Document Type: Article

References (47)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-395. (Pubitemid 30208155)
2. Prager GW, Breuss JM, Steurer S, et al. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res. 2004;94(12):1562-1570. (Pubitemid 38856963)
3. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood. 2004;103(3):955-962. (Pubitemid 38129556)
4. Herz J, Clouthier DE, Hammer RE. LDL receptorrelated protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71(3):411-421.
5. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997;16(10):2610-2620. (Pubitemid 27226200)
6. Serrati S, Margheri F, Fibbi G, et al. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression. J Pathol. 2008;214(5):545-554. (Pubitemid 351492460)
7. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res. 2008;14(18):5785-5793.
8. Andronicos NM, Chen EI, Baik N, et al. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood. 2010;115(7):1319-1330.
9. Magdolen V, Kruger A, Sato S, et al. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Recent Results Cancer Res. 2003;162:43-63.
10. Prager GW, Mihaly J, Brunner PM, Koshelnick Y, Hoyer-Hansen G, Binder BR. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood. 2009;113(6):1383-1390.
11. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97(3):336-342. (Pubitemid 46437793)
12. Fagotto F, Gumbiner BM. Cell contact-dependent signaling. Dev Biol. 1996;180(2):445-454. (Pubitemid 27037353)
13. Grazia Lampugnani M, Zanetti A, Corada M, et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, betacatenin, and the phosphatase DEP-1/CD148. J Cell Biol. 2003;161(4):793-804. (Pubitemid 36648762)
14. Vinals F, Pouyssegur J. Confluence of vascular endothelial cells induces cell cycle exit by inhibiting p42/p44 mitogen-activated protein kinase activity. Mol Cell Biol. 1999;19(4):2763-2772. (Pubitemid 29144520)
15. Takahashi T, Takahashi K, Mernaugh RL, Tsuboi N, Liu H, Daniel TO. A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. Blood. 2006;108(4):1234-1242. (Pubitemid 44232020)
16. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J. 1993;12(9):3551-3558. (Pubitemid 23256442)
17. Lucerna M, Mechtcheriakova D, Kadl A, et al. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem. 2003;278(13):11433- 11440. (Pubitemid 36792702)
18. Gruber F, Hufnagl P, Hofer-Warbinek R, et al. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. Blood. 2003;101(8):3042-3048. (Pubitemid 36857993)
19. Pfaffl MW. A new mathematical model for relativ quantification in real-time RT-PCR. Nucleic Acid Res. 2001;29(9):e45.
20. Ponce ML. Tube formation: an in vitro matrigel angiogenesis assay. Methods Mol Biol. 2009;46:183-188.
21. Serrati S, Cinelli M, Margheri F, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210(2):240-248. (Pubitemid 44463939)
22. Hoyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267(25):18224-18229.
23. Ronne E, Behrendt N, Ellis V, Ploug M, Dano K, Hoyer-Hansen G. Cell-induced potentiation of th plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 1991;288(1):233-236.
24. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997;420(1):79-85. (Pubitemid 28037204)
25. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett. 2000;470(1):40-46. (Pubitemid 30155620)
26. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995;270(25):14843-14846.
27. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9(9):726-735.
28. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80(2):179-185.
29. Lund LR, Ellis V, Ronne E, Pyke C, Dano K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J. 1995;310(1):345-352.
30. Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, Terao T. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem. 2002;269(16):3945-3957. (Pubitemid 34994889)
31. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 2007;26(22):3203-3213. (Pubitemid 46763015)
32. Sacco F, Tinti M, Palma A, et al. Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases. J Biol Chem. 2009;284(33):22048-22058.
33. Yang SH, Sharrocks AD. Convergence of the SUMO and MAPK pathways on the ETS-domain transcription factor Elk-1. Biochem Soc Symp. 2006;73:121-129. (Pubitemid 44884519)
34. Ostman A, Yang Q, Tonks NK. Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. Proc Natl Acad Sci U S A. 1994;91(21):9680-9684. (Pubitemid 24311871)
35. Borges LG, Seifert RA, Grant FJ, et al. Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells. Circ Res. 1996;79(3):570-580. (Pubitemid 26276917)
36. Kuramochi S, Matsuda S, Matsuda Y, Saitoh T, Ohsugi M, Yamamoto T. Molecular cloning and characterization of Byp, a murine receptor-type tyrosine phosphatase similar to human DEP-1. FEBS Lett. 1996;378(1):7-14. (Pubitemid 26007868)
37. Kroon ME, Koolwijk P, van Goor H, et al. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol. 1999;154(6):1731-1742. (Pubitemid 29262855)
38. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56(10):2428-2433. (Pubitemid 26154094)
39. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci. 2008;13:6752-6762.
40. Wells JM, Strickland S. Regulated localization confers multiple functions on the protease urokinase plasminogen activator. J Cell Physiol. 1997;171(2):217-225. (Pubitemid 27205064)
41. Sorby M, Sandstrom J, Ostman A. An extracellular ligand increases the specific activity of the receptor-like protein tyrosine phosphatase DEP-1. Oncogene. 2001;20(37):5219-5224. (Pubitemid 32844052)
42. Kappert K, Paulsson J, Sparwel J, et al. Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J. 2007;21(2):523-534. (Pubitemid 46213499)
43. Jandt E, Denner K, Kovalenko M, Ostman A, Bohmer FD. The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion. Oncogene. 2003;22(27):4175-4185. (Pubitemid 36876238)
44. Takahashi T, Takahashi K, St John PL, et al. A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol. 2003;23(5):1817-1831. (Pubitemid 36246061)
45. Balavenkatraman KK, Jandt E, Friedrich K, et al. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients. Oncogene. 2006;25(47):6319-6324. (Pubitemid 44564747)
46. Kellie S, Craggs G, Bird IN, Jones GE. The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements, aberrant cell-substratum interactions and a reduction in cell proliferation. J Cell Sci. 2004;117(4):609-618. (Pubitemid 38240202)
47. Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VW. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillarylike tube formation in a fibrin matrix. Blood. 2000;96(8):2775-2783.